In a byline article for Pharma IQ, Goodwin partner Natasha Daughtrey, who serve in the Intellectual Property Litigation group, share insight on how European developers can successfully launch a biosimilar in the U.S. Read the article here.
Related Content
- AlertMarch 12, 2024
USPTO’s New Guidance on AI-Assisted Inventions: The Impact on the Use of AI in the Life Sciences
- AlertFebruary 13, 2024
USPTO Issues New Guidance on Patenting AI-Assisted Inventions
- InsightJanuary 16, 2024
What’s Next for AI? Six Areas to Watch in 2024
- InsightNovember 30, 2023
How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code
- InsightOctober 31, 2023
Coding with AI in an Open-Source World
- AlertAugust 30, 2023
In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges
- AlertAugust 29, 2023
Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding
- AlertJuly 17, 2023
Sens. Tillis and Coons Propose New Legislation Regarding Patentability Under § 101
- Speaking EngagementsApril 29, 2024 | 10:15 AM - 11:15 AM PT
PLI's Patent Law Institute 2024: Critical Issues & Best Practices San Francisco
- EventsApril 24, 2024
Dispute Resolution in the Life Sciences Industry
- Speaking EngagementsApril 24, 2024
IP Leadership Executive North America 2024
- Press ReleaseApril 15, 2024
Fox Robotics Enters Multi-Year Agreement with Walmart
- Press ReleaseApril 15, 2024
Goodwin Advises Exclusive Placement Agent in Acrivon Therapeutics’ $130 Million Private Placement
- Press ReleaseApril 10, 2024
Auradine Raises $80 Million in Series B Financing and Achieves $80 Million in Bookings
- Press ReleaseMarch 29, 2024
Terragia Biofuel Completes $6 Million Seed Round
- Speaking EngagementsMarch 28, 2024
The Fate of the Therapeutic Dosing Regimen: Trends and Considerations in Validity Challenges to Dosing Patent Claims